[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-001", "question": "A 58-year-old man with a history of hypertrophic cardiomyopathy presents with recurrent syncope. Genetic testing reveals a mutation in the MYH7 gene. Echocardiography shows asymmetric septal hypertrophy with a left ventricular outflow tract gradient of 80 mmHg at rest. Despite optimal medical therapy with beta-blockers, he continues to experience symptoms. What is the most appropriate next step in management?", "options": ["Alcohol septal ablation", "Surgical myectomy", "Implantation of a dual-chamber pacemaker", "Addition of disopyramide", "Cardiac resynchronization therapy"], "answer": "D", "answer_index": 3, "explanation": "Addition of disopyramide is the most appropriate next step as it is recommended for symptomatic hypertrophic cardiomyopathy with obstruction refractory to beta-blockers, acting as a negative inotrope to reduce the gradient. Alcohol septal ablation and surgical myectomy are invasive options considered only after failure of medical therapy including disopyramide. Pacemaker implantation and cardiac resynchronization therapy are not first-line for outflow tract obstruction in this context.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nThe patient has:\n- Hypertrophic cardiomyopathy (HCM) with MYH7 mutation\n- Recurrent syncope (high-risk symptom)\n- Asymmetric septal hypertrophy\n- Severe LVOT obstruction (gradient 80 mmHg at rest - significantly elevated, >30 mmHg is considered obstructive)\n- Already on optimal beta-blocker therapy but still symptomatic\n\nLet me evaluate each option:\n\nA. Alcohol septal ablation - This is a percutaneous option for septal reduction therapy, typically considered when surgical myectomy is not preferred or patient is not a surgical candidate.\n\nB. Surgical myectomy - This is the gold standard for septal reduction therapy in patients with obstructive HCM who remain symptomatic despite optimal medical therapy. It has excellent long-term outcomes and is preferred, especially in younger patients and those with significant septal thickness.\n\nC. Dual-chamber pacemaker - This was previously used but has fallen out of favor as primary therapy for LVOT obstruction. It may provide modest benefit but is not first-line for symptomatic relief.\n\nD. Addition of disopyramide - This is a class IA antiarrhythmic with negative inotropic properties that can reduce LVOT gradient. However, the question states he's on \"optimal medical therapy\" which typically would include disopyramide if indicated. Also, with recurrent syncope and such a high gradient, septal reduction therapy is more appropriate.\n\nE. Cardiac resynchronization therapy - Not indicated for HCM with LVOT obstruction.\n\nGiven that:\n1. The patient has failed optimal medical therapy\n2. Has severe symptoms (recurrent syncope)\n3. Has significant LVOT obstruction (80 mmHg)\n4. Is relatively young (58 years)\n\nAccording to guidelines, surgical septal myectomy is the preferred intervention for drug-refractory symptomatic obstructive HCM, particularly when performed at experienced centers. It is considered the gold standard with proven long-term efficacy and safety.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-002", "question": "A 4-year-old boy with a history of recurrent urinary tract infections is found to have vesicoureteral reflux on voiding cystourethrogram. Renal ultrasound shows mild hydronephrosis. Despite prophylactic antibiotics, he develops breakthrough infections. Genetic evaluation reveals a mutation in the PAX2 gene. What is the most likely associated syndrome?", "options": ["Denys-Drash syndrome", "Renal coloboma syndrome", "Branchio-oto-renal syndrome", "Alport syndrome", "Frasier syndrome"], "answer": "B", "answer_index": 1, "explanation": "Renal coloboma syndrome is associated with PAX2 mutations, characterized by renal hypoplasia, vesicoureteral reflux, and optic nerve colobomas. Denys-Drash and Frasier syndromes involve WT1 mutations, while Alport syndrome relates to collagen IV defects. Branchio-oto-renal syndrome is linked to EYA1 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me work through this question systematically.\n\nThe key information provided:\n- 4-year-old boy with recurrent UTIs\n- Vesicoureteral reflux (VUR)\n- Mild hydronephrosis\n- Breakthrough infections despite prophylactic antibiotics\n- PAX2 gene mutation\n\nLet me analyze each option:\n\nA. Denys-Drash syndrome - Caused by WT1 gene mutations. Associated with nephropathy, Wilms tumor, and disorders of sexual development.\n\nB. Renal coloboma syndrome (also called Papillorenal syndrome) - Caused by PAX2 gene mutations. Characterized by optic nerve colobomas and renal abnormalities including renal hypoplasia, vesicoureteral reflux, and other urinary tract anomalies.\n\nC. Branchio-oto-renal syndrome - Caused by EYA1, SIX1, or SIX5 gene mutations. Associated with branchial arch anomalies, hearing loss, and renal abnormalities.\n\nD. Alport syndrome - Caused by mutations in COL4A3, COL4A4, or COL4A5 genes (collagen genes). Associated with progressive nephritis, hearing loss, and eye abnormalities.\n\nE. Frasier syndrome - Caused by WT1 gene mutations (specifically intron 9 splice site mutations). Associated with progressive glomerulopathy and disorders of sexual development.\n\nThe PAX2 gene is specifically associated with Renal coloboma syndrome. PAX2 is a transcription factor crucial for kidney and eye development. Mutations lead to:\n- Renal abnormalities (hypoplasia, VUR, hydronephrosis)\n- Optic nerve colobomas\n- Hearing loss (in some cases)\n\nThe clinical presentation of VUR with hydronephrosis and recurrent UTIs, combined with the PAX2 mutation, points directly to Renal coloboma syndrome.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-003", "question": "In the emergency department, a 32-year-old woman presents with acute chest pain and dyspnea following a long-haul flight. CT pulmonary angiography confirms a segmental pulmonary embolism. She has a history of oral contraceptive use and a positive family history for thrombophilia. Laboratory testing shows elevated factor VIII levels. What is the most appropriate initial anticoagulant therapy?", "options": ["Low-molecular-weight heparin followed by warfarin", "Direct oral anticoagulant such as rivaroxaban", "Unfractionated heparin with thrombolysis", "Fondaparinux monotherapy", "Aspirin and clopidogrel combination"], "answer": "B", "answer_index": 1, "explanation": "Direct oral anticoagulants like rivaroxaban are preferred for initial treatment of pulmonary embolism in non-pregnant patients without severe renal impairment or active cancer. Low-molecular-weight heparin followed by warfarin is an alternative but less convenient. Thrombolysis is reserved for hemodynamically unstable cases, and antiplatelet therapy is insufficient for venous thromboembolism.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nPatient Profile:\n- 32-year-old woman\n- Acute PE (segmental) confirmed on CTPA\n- Risk factors: OCP use, family history of thrombophilia, elevated factor VIII\n- Presenting with chest pain and dyspnea\n\nKey Considerations:\n\n1. Severity Assessment: This appears to be a non-massive (submassive or low-risk) PE - she has symptoms but there's no mention of hemodynamic instability (hypotension, shock), right heart strain, or elevated troponin/BNP suggesting high-risk PE.\n\n2. Treatment Options Analysis:\n\n- Option A (LMWH + Warfarin): Traditional approach, effective but requires bridging and INR monitoring\n- Option B (DOAC - rivaroxaban): Current guideline-recommended first-line therapy for acute PE in hemodynamically stable patients. DOACs are preferred over warfarin due to convenience, no monitoring needed, and similar or better safety profile\n- Option C (UFH + thrombolysis): Reserved for massive PE with hemodynamic instability - not indicated here\n- Option D (Fondaparinux monotherapy): Not appropriate as monotherapy; needs transition to oral anticoagulation\n- Option E (Aspirin + clopidogrel): Antiplatelet therapy is not appropriate for VTE treatment\n\n3. Current Guidelines: For hemodynamically stable PE, DOACs (rivaroxaban, apixaban, edoxaban, dabigatran) are now recommended as first-line therapy over vitamin K antagonists by major guidelines (ACCP, ESC).\n\n4. Special Considerations: While she has elevated factor VIII and possible thrombophilia, this doesn't change the initial anticoagulation choice. DOACs are appropriate for most thrombophilia patients (except antiphospholipid syndrome with triple positivity).\n\nThe most appropriate initial therapy for this hemodynamically stable patient with acute PE is a DOAC.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-004", "question": "A 45-year-old woman presents with symmetric polyarthritis, morning stiffness, and a rash on her trunk. Laboratory tests show positive anti-citrullinated protein antibodies and elevated inflammatory markers. Despite methotrexate therapy, her disease progresses. Genetic testing reveals a mutation in the NLRP3 gene. What is the most likely diagnosis?", "options": ["Rheumatoid arthritis", "Cryopyrin-associated periodic syndrome", "Adult-onset Still's disease", "Behçet's disease", "Systemic lupus erythematosus"], "answer": "B", "answer_index": 1, "explanation": "Cryopyrin-associated periodic syndrome involves NLRP3 mutations, presenting with arthritis, rash, and autoinflammatory features that may mimic rheumatoid arthritis but respond poorly to standard DMARDs. Rheumatoid arthritis typically lacks this genetic mutation and responds to methotrexate. Adult-onset Still's disease and others do not feature NLRP3 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nThe patient presents with:\n- Symmetric polyarthritis\n- Morning stiffness\n- Rash on trunk\n- Positive anti-citrullinated protein antibodies (anti-CCP)\n- Elevated inflammatory markers\n- Poor response to methotrexate\n- NLRP3 gene mutation\n\nKey considerations:\n\nAnti-CCP antibodies are highly specific for rheumatoid arthritis (RA), which would explain the symmetric polyarthritis and morning stiffness.\n\nHowever, the NLRP3 gene mutation is the critical finding here. NLRP3 encodes cryopyrin, a component of the inflammasome. Mutations in NLRP3 cause Cryopyrin-Associated Periodic Syndromes (CAPS), which include:\n- Familial Cold Autoinflammatory Syndrome (FCAS)\n- Muckle-Wells Syndrome\n- Neonatal-Onset Multisystem Inflammatory Disease (NOMID)\n\nCAPS can present with:\n- Urticarial-like rash\n- Arthritis/arthralgia\n- Elevated inflammatory markers\n- Poor response to conventional DMARDs like methotrexate\n\nThe presence of anti-CCP antibodies is unusual for CAPS, but the question specifically asks about the diagnosis given the NLRP3 mutation. CAPS patients typically respond to IL-1 inhibitors (like anakinra) rather than methotrexate, which explains the treatment failure.\n\nWhile the anti-CCP positivity might suggest RA, the NLRP3 mutation is pathognomonic for CAPS. The question seems to be testing whether you recognize that the genetic finding (NLRP3 mutation) points to a specific diagnosis that would explain the clinical presentation and treatment resistance.\n\nAdult-onset Still's disease can have similar features but is not associated with NLRP3 mutations. SLE and Behçet's have different presentations and genetic associations.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-005", "question": "A 28-year-old man with type 1 diabetes mellitus presents with recurrent hypoglycemia despite insulin dose adjustments. Continuous glucose monitoring shows nocturnal hypoglycemia. Laboratory evaluation reveals elevated proinsulin levels and a low C-peptide. What is the most likely underlying mechanism?", "options": ["Insulinoma", "Factitious hypoglycemia from exogenous insulin", "Adrenal insufficiency", "Autoimmune hypoglycemia", "Nesidioblastosis"], "answer": "B", "answer_index": 1, "explanation": "Factitious hypoglycemia from exogenous insulin is indicated by low C-peptide and elevated proinsulin due to suppressed endogenous insulin production. Insulinoma would show high C-peptide and proinsulin. Adrenal insufficiency typically causes hyperglycemia, and autoimmune hypoglycemia involves insulin antibodies with variable C-peptide.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nThe patient has:\n- Type 1 diabetes mellitus\n- Recurrent hypoglycemia\n- Nocturnal hypoglycemia on CGM\n- Elevated proinsulin levels\n- LOW C-peptide\n\nKey laboratory findings to interpret:\n- C-peptide is LOW: This indicates suppressed endogenous insulin production\n- Proinsulin is ELEVATED: This seems contradictory at first\n\nWait, let me reconsider. In a patient with type 1 diabetes taking exogenous insulin:\n- If using exogenous insulin, endogenous insulin production would be suppressed\n- C-peptide would be low (as it's co-secreted with endogenous insulin)\n- Commercial insulin preparations can contain proinsulin as a contaminant\n\nActually, I need to reconsider the proinsulin finding. In factitious hypoglycemia from exogenous insulin:\n- C-peptide is LOW (suppressed endogenous production)\n- Insulin levels would be HIGH\n- Proinsulin would typically be LOW (not elevated)\n\nLet me reconsider insulinoma:\n- Would show HIGH C-peptide and HIGH proinsulin\n- This doesn't match (C-peptide is low)\n\nFor autoimmune hypoglycemia (insulin autoimmune syndrome):\n- Would show high insulin levels with variable C-peptide\n\nWait - I need to reconsider. The question states \"elevated proinsulin\" with \"low C-peptide.\" \n\nIn factitious hypoglycemia with exogenous insulin:\n- Exogenous insulin suppresses endogenous insulin secretion\n- C-peptide is LOW\n- Some older or certain insulin preparations may contain proinsulin-like immunoreactivity\n\nHowever, the classic pattern for factitious insulin use is:\n- High insulin\n- Low C-peptide\n- Low proinsulin\n\nGiven the combination of LOW C-peptide with elevated proinsulin in a type 1 diabetic, the most likely explanation is factitious hypoglycemia from exogenous insulin administration. The low C-peptide confirms suppressed endogenous insulin production, which is the hallmark of exogenous insulin use.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-006", "question": "A 65-year-old man with ischemic cardiomyopathy and an ejection fraction of 25% develops sustained ventricular tachycardia. He is hemodynamically stable. Electrophysiology study identifies a reentrant circuit in the infarct border zone. Despite amiodarone therapy, episodes recur. What is the most appropriate next intervention?", "options": ["Catheter ablation", "Implantable cardioverter-defibrillator upgrade to biventricular", "Addition of mexiletine", "Stellate ganglionectomy", "Cardiac sympathetic denervation"], "answer": "A", "answer_index": 0, "explanation": "Catheter ablation is the most appropriate for recurrent ventricular tachycardia in ischemic cardiomyopathy refractory to antiarrhythmic drugs, targeting the reentrant circuit. ICD upgrade addresses heart failure but not arrhythmia substrate directly. Mexiletine addition is less effective for scar-related VT, and surgical options like ganglionectomy are reserved for refractory cases.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Let me analyze this case systematically.\n\nThe patient has:\n- Ischemic cardiomyopathy with EF 25%\n- Sustained ventricular tachycardia (VT)\n- Hemodynamically stable\n- EP study showing reentrant circuit in infarct border zone\n- Failed amiodarone therapy with recurrent episodes\n\nKey considerations:\n\nOption A - Catheter ablation: This is the standard of care for drug-refractory VT, especially when a reentrant circuit has been identified in the infarct border zone. The EP study has already mapped the circuit, making ablation a targeted intervention. Guidelines recommend catheter ablation for patients with recurrent VT despite antiarrhythmic drug therapy.\n\nOption B - Upgrade to biventricular ICD: While this patient likely needs an ICD (if not already present), upgrading to biventricular pacing (CRT) is indicated for heart failure management with LBBB and wide QRS, not specifically for VT suppression.\n\nOption C - Addition of mexiletine: Adding a second antiarrhythmic (Class IB) to amiodarone can be considered, but given that a specific reentrant circuit has been identified and amiodarone has failed, ablation would be more definitive.\n\nOption D - Stellate ganglionectomy: This is typically reserved for refractory cases after ablation has failed, particularly for VT storm.\n\nOption E - Cardiac sympathetic denervation: Similar to stellate ganglionectomy, this is a more aggressive intervention reserved for cases refractory to both drugs and ablation.\n\nGiven that:\n1. The patient has drug-refractory VT\n2. A specific anatomical substrate (reentrant circuit in infarct border zone) has been identified\n3. He is hemodynamically stable (good candidate for ablation)\n\nCatheter ablation is the most appropriate next step according to current guidelines for management of ventricular arrhythmias.\n\nThe answer is (A)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-007", "question": "An 8-year-old girl with short stature and failure to thrive undergoes evaluation. Bone age is delayed, and laboratory tests show low IGF-1 with normal growth hormone stimulation. Genetic testing reveals a mutation in the IGF1R gene. What is the most appropriate management strategy?", "options": ["Recombinant growth hormone therapy", "IGF-1 replacement therapy", "Nutritional supplementation", "Thyroid hormone replacement", "Corticosteroid therapy"], "answer": "B", "answer_index": 1, "explanation": "IGF-1 replacement therapy is indicated for IGF1R mutations causing primary IGF-1 deficiency resistant to growth hormone. Recombinant growth hormone would be ineffective due to receptor defect. Nutritional or hormonal supplements like thyroid or corticosteroids do not address the underlying IGF-1 resistance.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Let me analyze this case systematically.\n\nThe patient is an 8-year-old girl with:\n- Short stature and failure to thrive\n- Delayed bone age\n- Low IGF-1\n- Normal growth hormone stimulation test\n- Mutation in the IGF1R gene\n\nThe IGF1R gene encodes the IGF-1 receptor. A mutation in this gene would cause IGF-1 resistance - meaning even if IGF-1 is present, the cells cannot respond properly to it.\n\nLet me consider each option:\n\nA. Recombinant growth hormone therapy - GH works primarily by stimulating IGF-1 production. Since GH stimulation is normal, the problem isn't GH deficiency. However, high-dose GH could potentially increase IGF-1 levels enough to partially overcome receptor resistance.\n\nB. IGF-1 replacement therapy - The patient has low IGF-1, but the primary problem is the IGF-1 receptor mutation. Simply giving more IGF-1 may not be effective if the receptor is defective. However, supraphysiologic doses might help overcome partial receptor resistance.\n\nC. Nutritional supplementation - Not the primary issue here as this is a genetic condition.\n\nD. Thyroid hormone replacement - No indication of thyroid dysfunction.\n\nE. Corticosteroid therapy - Would actually impair growth further.\n\nIn IGF1R mutations, the receptor has reduced sensitivity to IGF-1. The low IGF-1 levels seen could be secondary to the receptor defect affecting feedback mechanisms. \n\nFor IGF1R mutations with IGF-1 resistance, high-dose recombinant GH therapy is typically tried first as it can increase circulating IGF-1 levels significantly, potentially overcoming partial receptor resistance. Some patients with IGF1R mutations do respond to GH therapy.\n\nIGF-1 replacement (mecasermin) is typically used for primary IGF-1 deficiency (like GH receptor defects/Laron syndrome) where GH is high but IGF-1 is low. In IGF1R mutations, giving IGF-1 directly may have limited benefit due to the receptor defect.\n\nGiven that GH therapy can increase IGF-1 levels and potentially overcome partial receptor resistance, and is the more commonly used first-line approach for IGF1R mutations:\n\nThe answer is A"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-008", "question": "In the emergency department, a 50-year-old man presents with severe abdominal pain and vomiting. CT scan shows acute pancreatitis with necrosis. He develops hypotension and acute kidney injury. Serum triglycerides are 1200 mg/dL. What is the most appropriate initial management for the hypertriglyceridemia?", "options": ["Plasmapheresis", "Insulin infusion", "Fibrates", "Niacin", "Statins"], "answer": "B", "answer_index": 1, "explanation": "Insulin infusion effectively lowers triglycerides in hypertriglyceridemic pancreatitis by enhancing lipoprotein lipase activity. Plasmapheresis is reserved for severe cases not responding to insulin. Fibrates, niacin, and statins are long-term therapies not suitable for acute management.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "In this case, we have a patient with severe acute pancreatitis with necrosis, likely caused by severe hypertriglyceridemia (triglycerides 1200 mg/dL - levels >1000 mg/dL are associated with pancreatitis risk). The patient is critically ill with hypotension and acute kidney injury.\n\nLet me analyze each option:\n\nA. Plasmapheresis - Can rapidly lower triglyceride levels and is sometimes used in severe cases, but it's invasive, expensive, and not universally available.\n\nB. Insulin infusion - Insulin activates lipoprotein lipase, which breaks down triglycerides. It works rapidly (within hours), is readily available, safe, and can be easily administered in the ICU setting. This is considered first-line therapy for acute severe hypertriglyceridemia-induced pancreatitis.\n\nC. Fibrates - These are oral medications that lower triglycerides but take days to weeks to work. Not appropriate for acute management, especially in a patient who is vomiting and critically ill.\n\nD. Niacin - Also an oral medication with delayed onset of action. Not suitable for acute management.\n\nE. Statins - Primarily lower LDL cholesterol with modest effects on triglycerides. Not the treatment of choice for severe hypertriglyceridemia.\n\nIn the acute setting with severe hypertriglyceridemia-induced pancreatitis, insulin infusion is the most appropriate initial management. It rapidly reduces triglyceride levels by activating lipoprotein lipase, is readily available, and can be safely administered with glucose monitoring. While plasmapheresis is also effective, insulin infusion is more practical as first-line therapy and is widely recommended in guidelines.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-009", "question": "A 35-year-old woman with seropositive rheumatoid arthritis on infliximab develops fever, weight loss, and lymphadenopathy. Biopsy shows non-caseating granulomas. Serum angiotensin-converting enzyme is elevated. What is the most likely diagnosis?", "options": ["Tuberculosis reactivation", "Infliximab-induced sarcoidosis", "Lymphoma", "Fungal infection", "Amyloidosis"], "answer": "B", "answer_index": 1, "explanation": "Infliximab-induced sarcoidosis is a rare complication of TNF inhibitors, presenting with granulomatous inflammation mimicking sarcoidosis. Tuberculosis would show caseating granulomas and positive cultures. Lymphoma or infections are differentials but less likely without specific evidence.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nThe patient has:\n- Rheumatoid arthritis on infliximab (a TNF-α inhibitor)\n- Fever, weight loss, lymphadenopathy\n- Non-caseating granulomas on biopsy\n- Elevated serum ACE\n\nKey considerations:\n\nTuberculosis reactivation (A): TNF-α inhibitors are well-known to cause TB reactivation. However, TB typically shows CASEATING granulomas, not non-caseating. This makes TB less likely given the biopsy findings.\n\nInfliximab-induced sarcoidosis (B): This is a recognized paradoxical reaction to TNF-α inhibitors. Despite TNF-α being involved in granuloma formation (and TNF inhibitors being used to treat sarcoidosis), there are documented cases of sarcoid-like reactions developing during anti-TNF therapy. The presentation with non-caseating granulomas and elevated ACE is classic for sarcoidosis.\n\nLymphoma (C): While TNF inhibitors may increase lymphoma risk, lymphoma would not typically present with non-caseating granulomas and elevated ACE.\n\nFungal infection (D): TNF inhibitors increase risk of fungal infections, and some can cause granulomatous reactions. However, fungal granulomas are often necrotizing/caseating, and elevated ACE is more specific for sarcoidosis.\n\nAmyloidosis (E): This would show amyloid deposits on biopsy, not granulomas.\n\nThe combination of:\n- Non-caseating granulomas\n- Elevated ACE\n- Patient on TNF-α inhibitor\n\nPoints strongly to drug-induced sarcoidosis, which is a well-documented paradoxical reaction to anti-TNF therapy including infliximab.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-010", "question": "A 42-year-old woman with acromegaly undergoes transsphenoidal surgery, but IGF-1 levels remain elevated postoperatively. She declines further surgery. What is the most appropriate pharmacologic therapy?", "options": ["Cabergoline", "Pegvisomant", "Octreotide", "Pasireotide", "Bromocriptine"], "answer": "B", "answer_index": 1, "explanation": "Pegvisomant, a growth hormone receptor antagonist, is the most effective for normalizing IGF-1 in acromegaly resistant to surgery and somatostatin analogs. Octreotide and pasireotide are somatostatin analogs that may not suffice post-surgery. Dopamine agonists like cabergoline or bromocriptine are less potent for pure GH-secreting adenomas.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "In this case, we have a patient with acromegaly who has persistent disease after transsphenoidal surgery (elevated IGF-1 levels) and declines further surgery.\n\nLet me analyze the options:\n\nSomatostatin analogs (Octreotide, Pasireotide):\n- First-line medical therapy for acromegaly after failed surgery\n- Octreotide (C) binds to somatostatin receptor subtypes 2 and 5\n- Pasireotide (D) has broader receptor binding but is typically reserved for cases resistant to first-generation somatostatin analogs\n\nDopamine agonists (Cabergoline, Bromocriptine):\n- Cabergoline (A) can be used but is less effective than somatostatin analogs\n- Bromocriptine (E) is even less effective than cabergoline\n- These are typically used as adjunctive therapy or in mild cases\n\nGH receptor antagonist (Pegvisomant):\n- Pegvisomant (B) blocks GH action at the receptor level\n- Very effective at normalizing IGF-1\n- Typically reserved as second-line therapy when somatostatin analogs fail or are not tolerated\n- Does not reduce tumor size\n\nFirst-line medical therapy for acromegaly after unsuccessful surgery is a somatostatin analog, specifically octreotide (or lanreotide). These medications:\n- Suppress GH secretion\n- Can reduce tumor size\n- Normalize IGF-1 in approximately 50-70% of patients\n\nOctreotide is the most appropriate first-line pharmacologic therapy in this scenario.\n\nThe answer is (C)"}]